Orchard Therapeutics PLC
Hazel O'Connor is currently the Senior Director at Orchard Therapeutics, showcasing a wealth of experience in technical operations, business operations, strategy, and alliance management. Prior to their current role, Hazel held leadership positions at Lonza, Hazel O'Connor Consultancy Limited, Terumo BCT, Actavis, NDA Analytics, and Emergent BioSolutions. With a background in Applied Biological Science, Hazel has demonstrated expertise in project and program management, analytical development, and manufacturing assay development throughout their career.
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.